History of autoimmune conditions and lymphoma prognosis

Geffen Kleinstern, Matthew J. Maurer, Mark Liebow, Thomas Matthew Habermann, Jean L. Koff, Cristine Allmer, Thomas Elmer Witzig, Grzegorz S Nowakowski, Ivana Micallef, Patrick Bruce Johnston, David J. Inwards, Carrie A Thompson, Andrew L Feldman, Brian K. Link, Christopher Flowers, Susan L Slager, James R Cerhan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Autoimmune conditions are strong risk factors for developing lymphoma, but their role in lymphoma prognosis is less clear. In a prospective cohort study, we evaluated self-reported history of eight autoimmune conditions with outcomes in 736 diffuse large B-cell, 703 follicular, 302 marginal zone (MZL), 193 mantle cell (MCL), 297 Hodgkin lymphoma (HL), and 186 T-cell lymphomas. We calculated event-free survival (EFS) and overall survival (OS), and estimated hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for sex, prognostic score, and treatment. History of any of the eight autoimmune conditions ranged from 7.4% in HL to 18.2% in MZL, and was not associated with EFS or OS for any lymphoma subtype. However, there was a positive association of autoimmune conditions primarily mediated by B-cell responses with inferior EFS in MCL (HR = 2.23, CI: 1.15–4.34) and HL (HR = 2.63, CI: 1.04–6.63), which was largely driven by rheumatoid arthritis. Autoimmune conditions primarily mediated by T-cell responses were not found to be associated with EFS or OS in any lymphoma subtype, although there were few events for this exposure. Our results indicate that distinguishing autoimmune conditions primarily mediated by B-cell/T-cell responses may yield insight regarding the impact of this comorbid disease, affecting ~10% of lymphoma patients, on survival.

Original languageEnglish (US)
Article number73
JournalBlood Cancer Journal
Volume8
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Lymphoma
Disease-Free Survival
Hodgkin Disease
B-Lymphocytes
Survival
Confidence Intervals
T-Lymphocytes
T-Cell Lymphoma
Rheumatoid Arthritis
Cohort Studies
Prospective Studies
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

History of autoimmune conditions and lymphoma prognosis. / Kleinstern, Geffen; Maurer, Matthew J.; Liebow, Mark; Habermann, Thomas Matthew; Koff, Jean L.; Allmer, Cristine; Witzig, Thomas Elmer; Nowakowski, Grzegorz S; Micallef, Ivana; Johnston, Patrick Bruce; Inwards, David J.; Thompson, Carrie A; Feldman, Andrew L; Link, Brian K.; Flowers, Christopher; Slager, Susan L; Cerhan, James R.

In: Blood Cancer Journal, Vol. 8, No. 8, 73, 01.08.2018.

Research output: Contribution to journalArticle

@article{c7929bd30130430c85348d8546e84053,
title = "History of autoimmune conditions and lymphoma prognosis",
abstract = "Autoimmune conditions are strong risk factors for developing lymphoma, but their role in lymphoma prognosis is less clear. In a prospective cohort study, we evaluated self-reported history of eight autoimmune conditions with outcomes in 736 diffuse large B-cell, 703 follicular, 302 marginal zone (MZL), 193 mantle cell (MCL), 297 Hodgkin lymphoma (HL), and 186 T-cell lymphomas. We calculated event-free survival (EFS) and overall survival (OS), and estimated hazard ratios (HRs) and 95{\%} confidence intervals (CIs), adjusting for sex, prognostic score, and treatment. History of any of the eight autoimmune conditions ranged from 7.4{\%} in HL to 18.2{\%} in MZL, and was not associated with EFS or OS for any lymphoma subtype. However, there was a positive association of autoimmune conditions primarily mediated by B-cell responses with inferior EFS in MCL (HR = 2.23, CI: 1.15–4.34) and HL (HR = 2.63, CI: 1.04–6.63), which was largely driven by rheumatoid arthritis. Autoimmune conditions primarily mediated by T-cell responses were not found to be associated with EFS or OS in any lymphoma subtype, although there were few events for this exposure. Our results indicate that distinguishing autoimmune conditions primarily mediated by B-cell/T-cell responses may yield insight regarding the impact of this comorbid disease, affecting ~10{\%} of lymphoma patients, on survival.",
author = "Geffen Kleinstern and Maurer, {Matthew J.} and Mark Liebow and Habermann, {Thomas Matthew} and Koff, {Jean L.} and Cristine Allmer and Witzig, {Thomas Elmer} and Nowakowski, {Grzegorz S} and Ivana Micallef and Johnston, {Patrick Bruce} and Inwards, {David J.} and Thompson, {Carrie A} and Feldman, {Andrew L} and Link, {Brian K.} and Christopher Flowers and Slager, {Susan L} and Cerhan, {James R}",
year = "2018",
month = "8",
day = "1",
doi = "10.1038/s41408-018-0105-4",
language = "English (US)",
volume = "8",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - History of autoimmune conditions and lymphoma prognosis

AU - Kleinstern, Geffen

AU - Maurer, Matthew J.

AU - Liebow, Mark

AU - Habermann, Thomas Matthew

AU - Koff, Jean L.

AU - Allmer, Cristine

AU - Witzig, Thomas Elmer

AU - Nowakowski, Grzegorz S

AU - Micallef, Ivana

AU - Johnston, Patrick Bruce

AU - Inwards, David J.

AU - Thompson, Carrie A

AU - Feldman, Andrew L

AU - Link, Brian K.

AU - Flowers, Christopher

AU - Slager, Susan L

AU - Cerhan, James R

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Autoimmune conditions are strong risk factors for developing lymphoma, but their role in lymphoma prognosis is less clear. In a prospective cohort study, we evaluated self-reported history of eight autoimmune conditions with outcomes in 736 diffuse large B-cell, 703 follicular, 302 marginal zone (MZL), 193 mantle cell (MCL), 297 Hodgkin lymphoma (HL), and 186 T-cell lymphomas. We calculated event-free survival (EFS) and overall survival (OS), and estimated hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for sex, prognostic score, and treatment. History of any of the eight autoimmune conditions ranged from 7.4% in HL to 18.2% in MZL, and was not associated with EFS or OS for any lymphoma subtype. However, there was a positive association of autoimmune conditions primarily mediated by B-cell responses with inferior EFS in MCL (HR = 2.23, CI: 1.15–4.34) and HL (HR = 2.63, CI: 1.04–6.63), which was largely driven by rheumatoid arthritis. Autoimmune conditions primarily mediated by T-cell responses were not found to be associated with EFS or OS in any lymphoma subtype, although there were few events for this exposure. Our results indicate that distinguishing autoimmune conditions primarily mediated by B-cell/T-cell responses may yield insight regarding the impact of this comorbid disease, affecting ~10% of lymphoma patients, on survival.

AB - Autoimmune conditions are strong risk factors for developing lymphoma, but their role in lymphoma prognosis is less clear. In a prospective cohort study, we evaluated self-reported history of eight autoimmune conditions with outcomes in 736 diffuse large B-cell, 703 follicular, 302 marginal zone (MZL), 193 mantle cell (MCL), 297 Hodgkin lymphoma (HL), and 186 T-cell lymphomas. We calculated event-free survival (EFS) and overall survival (OS), and estimated hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for sex, prognostic score, and treatment. History of any of the eight autoimmune conditions ranged from 7.4% in HL to 18.2% in MZL, and was not associated with EFS or OS for any lymphoma subtype. However, there was a positive association of autoimmune conditions primarily mediated by B-cell responses with inferior EFS in MCL (HR = 2.23, CI: 1.15–4.34) and HL (HR = 2.63, CI: 1.04–6.63), which was largely driven by rheumatoid arthritis. Autoimmune conditions primarily mediated by T-cell responses were not found to be associated with EFS or OS in any lymphoma subtype, although there were few events for this exposure. Our results indicate that distinguishing autoimmune conditions primarily mediated by B-cell/T-cell responses may yield insight regarding the impact of this comorbid disease, affecting ~10% of lymphoma patients, on survival.

UR - http://www.scopus.com/inward/record.url?scp=85050969050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050969050&partnerID=8YFLogxK

U2 - 10.1038/s41408-018-0105-4

DO - 10.1038/s41408-018-0105-4

M3 - Article

C2 - 30069001

AN - SCOPUS:85050969050

VL - 8

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 8

M1 - 73

ER -